Clinical Research Directory
Browse clinical research sites, groups, and studies.
Rezafungin Prophylaxis in Liver Transplant
Sponsor: Fernanda P Silveira, MD, MS
Summary
This is an interventional study to evaluate the efficacy of rezafungin, a new echinocandin, for the prevention of invasive fungal infections (IFIs) after liver transplantation. Patients who receive rezafungin will be compared to a similar group of patients who underwent liver transplantation in the preceding two years for the incidence of IFIs.
Official title: Rezafungin Prophylaxis in Liver Transplant at High Risk for Invasive Fungal Infection
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
385
Start Date
2025-10-15
Completion Date
2028-12
Last Updated
2025-10-20
Healthy Volunteers
No
Interventions
Rezafungin
Rezafungin 400 mg IV once within 24 hours of liver transplant, followed by 200 mg IV weekly for 4 weeks.
Standard of care antifungal prophylaxis
UPMC uses a tiered approach to antifungal prophylaxis, based on risk factors for IFI. Fluconazole is used for recipients with risk factors for yeast infections: choledochojejunostomy, prolonged transplant time, receipt of \>40 units of blood products within 24 hours of transplant, and Candida colonization or infection within 3 months prior to transplant. Voriconazole is used for recipients with risk factors for mould infections: re-transplantation, renal failure requiring renal replacement therapy, fulminant hepatic failure as indication for transplant, intra-abdominal/thoracic re-exploration within the first month after transplant. No prophylaxis is given if there are no risk factors for yeast or mould infections.
Locations (1)
UPMC Presbyterian
Pittsburgh, Pennsylvania, United States